相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies
Amye J. Tevaarwerk et al.
CLINICAL CANCER RESEARCH (2009)
Activity of 2 methoxyestradiol (Panzem® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial
Daniela Matei et al.
GYNECOLOGIC ONCOLOGY (2009)
2-methoxyestradiol inhibits hypoxia-inducible factor-1α and suppresses growth of lesions in a mouse model of endometriosis
Christian M. Becker et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo
Christian Moser et al.
BMC CANCER (2008)
Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198
Theresa M. LaVallee et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer
Jehana James et al.
INVESTIGATIONAL NEW DRUGS (2007)
2-methoxyestradiol inhibits hypoxia-inducible factor lot, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma
JL Ricker et al.
CLINICAL CANCER RESEARCH (2004)
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
NJ Mabjeesh et al.
CANCER CELL (2003)
Mechanism of action of 2-methoxyestradiol: new developments
SL Mooberry
DRUG RESISTANCE UPDATES (2003)
分享论文
